PTC Therapeutics has signed a long-term lease agreement with Bristol-Myers Squibb (BMS) to acquire BMS biologics facility in New Jersey, PTC announced in an Aug. 5, 2019 press release. Under the agreement, PTC will gain access to approximately 185,000 ft2 of space, including an existing state-oOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.